{"id":"NCT02227862","sponsor":"Mylan Inc.","briefTitle":"Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)","officialTitle":"An Open-Label, Randomized, Multi-Center, Parallel-Group Clinical Trial Comparing the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-06","primaryCompletion":"2016-07","completion":"2016-07","firstPosted":"2014-08-28","resultsPosted":"2020-03-09","lastUpdate":"2022-03-03"},"enrollment":558,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Type 1 Diabetes"],"interventions":[{"type":"DRUG","name":"Mylan's insulin glargine","otherNames":[]},{"type":"DRUG","name":"Lantus®","otherNames":[]}],"arms":[{"label":"Mylan's Insulin Glargine","type":"EXPERIMENTAL"},{"label":"Lantus®","type":"ACTIVE_COMPARATOR"}],"summary":"To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.","primaryOutcome":{"measure":"Change in HbA1c From Baseline to 24 Weeks","timeFrame":"24 weeks","effectByArm":[{"arm":"Mylan's Insulin Glargine","deltaMin":0.14,"sd":0.054},{"arm":"Lantus®","deltaMin":0.11,"sd":0.054}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":162,"countries":["United States","Canada","Czechia","Estonia","Germany","Hungary","Latvia","Romania","Slovakia","South Africa","United Kingdom"]},"refs":{"pmids":["34174848"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":280},"commonTop":["Hypoglycaemia","Nasopharyngitis","Upper respiratory tract infection","Influenza","Headache"]}}